CC-99282
BMS
['nhl']
breaking data from #eha2022: cc-99282, a new celmod agent, in patients with r/r nhl demonstrated degradation of ikaros/aiolos in peripheral t cells in a dose-dependent manner with maximum degradation (&gt;90%) occuring by day 4 of treatment at doses 0.4mg in a phase 1 study 
Real time, on-demand personalized cancer education and support through our online educational platform